Navigation Links
Study finds greater potential benefit in overall survival for eribulin compared with capecitabine
Date:6/12/2013

(Lebanon, NH, 6/11/13) Subgroup analyses from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate, with capecitabine, a standard chemotherapy medication in women with previously treated metastatic breast cancer, showed increased benefit among women sharing certain traits. Specifically, these analyses demonstrated a greater potential benefit in certain subsets of patients with metastatic breast cancer. This analysis was presented by Peter A. Kaufman, M.D., during the 2013 ASCO Annual Meeting.

The specific patient populations who appeared to benefit from eribulin, in comparison to capecitabine, are as follows:

  • Patients with more than two organs involved with metastatic breast cancer
  • Patients who had not received chemotherapy for six months or longer
  • Patients who had received anthracycline and/or a taxane therapies in the metastatic setting

Previous pre-specified exploratory analysis of overall survival and progression-free survival showed women with triple-negative, ER-negative, HER2-negative also had a greater relative benefit in overall survival with eribulin over capecitabine.

"These exploratory analyses suggest that other patient subgroups may benefit from eribulin and further studies are warranted," said Peter A. Kaufman, MD, associate professor of medicine at the Geisel School of Medicine at Dartmouth, and oncologist at Dartmouth-Hitchcock and Norris Cotton Cancer Center in Lebanon, N.H.

In 2010, the FDA approved eribulin for the treatment of patients with metastatic breast cancer who had previously received an anthracycline and a taxane and at least two cytotoxic chemotherapy treatment regimens for metastatic breast cancer. The FDA granted approval based on data showing a statistically significant improvement in overall survival compared with current treatments.

Kaufman and colleagues are still compiling data from the quality-of-life analysis, which according to Kaufman, will help guide their next steps in further studying eribulin in this patient population.


'/>"/>

Contact: Donna Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Related medicine news :

1. New Study Links Poor Sleep and Prostate Cancer
2. Researcher awarded grant to study food insecurity in homes of child with special healthcare needs
3. Study finds cancer guidelines do not fully meet IOM standards
4. Our Lady of Lourdes Medical Center & The Heart House Participating in Research Study Using Adult Stem Cells for Chronic Cardiac Condition
5. High Bit Security: 2/3 of All Data Breaches Preventable With Proactive Security Testing, New Ponemon Institute Study Documents Breach Causes and Costs
6. Alzheimer's Pilot Study Proposed for Ustekinumab (Stelara)
7. Capital Health Institute's Study Shows Migraine Headaches Prevalent Among Teen Girls
8. Workers do not quit due to mandatory flu shot, says Loyola study
9. Study finds obese mothers program their kids to be fat, but legacy can be overturned
10. Study shows cardiac MRI use reduces adverse events for patients with acute chest pain
11. Great HealthWorks, Makers of Omega XL, Report on New Omega-3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's ... President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. ... 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  Caris Life ... focused on fulfilling the promise of precision medicine, today ... has joined Caris, Precision Oncology Alliance™ (POA) as its ... cancer centers, the St. Jude Crosson Cancer Institute will ... advance the use of tumor profiling, making cancer treatment ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology: